Description
The review highlights NLRP3 inflammasome and TREM2 as therapeutic targets while emphasizing the need to preserve protective immune functions. However, the specific criteria and mechanisms to selectively modulate harmful inflammation while maintaining beneficial immune responses are not defined. This represents a critical challenge for translating anti-inflammatory approaches to clinical practice.
Gap type: open_question Source paper: Systemic inflammation as a central player in the initiation and development of Alzheimer’s disease. (2025, Immunity & ageing : I & A, PMID:40841660)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:36.752612+00:00”, “resolution_summary”: “Resolved by hypothesis h-c58ac188fc: Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation. Supporting evidence includes debate sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c.”, “match_counts”: {“hypothesis_matches”: 5, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-c58ac188fc”, “title”: “Enhancing Microglial Phagocytosis of Extracellular Tau via TREM2 Activation”, “score”: 0.25, “reason”: “22 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-04-gap-tau-prion-spreading”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neuroscience”, “composite_score”: 0.770522, “confidence_score”: 0.82, “status”: “debated”, “pubmed_evidence_ids”: [“28803812”, “32403128”, “34429422”, “ClinicalTrials.gov”]}, {“id”: “h-7af6de6f2a”, “title”: “NLRP3 Inflammasome Lock Perpetuates Senescence-Associated Inflammasome Phenotype”, “score”: 0.25, “reason”: “22 token overlaps; entity overlap: nlrp3”, “analysis_id”: “SDA-2026-04-06-gap-pubmed-20260406-041439-5f43216e”, “target_gene”: “NLRP3/CASP1/IL1B”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.72, “confidence_score”: 0.72, “status”: “proposed”, “pubmed_evidence_ids”: [“30626958”, “31182948”, “31672832”, “ClinicalTrials.gov”]}, {“id”: “h-var-adfecef68a”, “title”: “Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-Synuclein Aggregates Drives Non-Cell-Autonomous Neurodegeneration”, “score”: 0.244, “reason”: “24 token overlaps; entity overlap: nlrp3”, “analysis_id”: “SDA-2026-04-01-gap-20260401-225149”, “target_gene”: “NLRP3, CASP1, IL1B, PYCARD”, “target_pathway”: “Astrocyte NLRP3 inflammasome activation by alpha-synuclein aggregate-driven lysosomal disruption”, “disease”: “neurodegeneration”, “composite_score”: 0.8220000000000001, “confidence_score”: 0.78, “status”: “proposed”, “pubmed_evidence_ids”: [“27519954”, “28506519”, “29263430”, “29643512”, “30610225”]}, {“id”: “h-d5dea85f”, “title”: “Microglial Senescence Prevention via TREM2/SASP Axis”, “score”: 0.24, “reason”: “22 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-16-gap-pubmed-20260410-150544-e3a2eab9”, “target_gene”: “TREM2”, “target_pathway”: null, “disease”: “neurodegeneration”, “composite_score”: 0.837096, “confidence_score”: 0.48, “status”: “proposed”, “pubmed_evidence_ids”: [“28602351”, “28802038”, “30738892”, “31902528”, “31932797”]}, {“id”: “SDA-2026-04-02-gap-tau-prop-20260402003221-H002”, “title”: “TREM2-mediated microglial tau clearance enhancement”, “score”: 0.24, “reason”: “26 token overlaps; entity overlap: trem2”, “analysis_id”: “SDA-2026-04-04-gap-tau-prop-20260402003221”, “target_gene”: “TREM2”, “target_pathway”: “TREM2/TYROBP microglial signaling”, “disease”: “neurodegeneration”, “composite_score”: 0.780383, “confidence_score”: 0.665, “status”: “proposed”, “pubmed_evidence_ids”: [“24990881”, “28602351”, “28802038”, “31932797”, “33516818”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “title”: “The abstract shows TYROBP deficiency is neuroprotective despite being required for TREM2, CD33, and CR3 function - receptors associated with AD risk. This counterintuitive finding challenges current understanding of how these immune receptors contribute to AD pathogenesis.\n\nGap type: contradiction\nSource paper: Deficiency of TYROBP, an adapter protein for TREM2 and CR3 receptors, is neuroprotective in a mouse model of early Alzheimer’s pathology. (None, None, PMID:28612290)”, “score”: 0.446, “reason”: “8 token overlaps; entity overlap: pmid, trem2”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260411-072446-a32fa49c”, “quality_score”: 0.56, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5”, “title”: “While the abstract identifies AQP4 as a ‘potential and promising target’ and mentions it could provide ‘new therapeutic alternatives,’ the specific approaches for therapeutic modulation of AQP4 function are not defined. This represents a critical translational gap for moving from mechanistic understanding to clinical intervention.\n\nGap type: open_question\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.429, “reason”: “12 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04”, “title”: “The abstract describes astrocyte phenotypic heterogeneity (A1/A2) but doesn’t explain the mechanistic switches governing this critical fate decision. Understanding these mechanisms is essential for therapeutic targeting of beneficial vs harmful astrocyte responses.\n\nGap type: unexplained_observation\nSource paper: Contribution of astrocytes to neuropathology of neurodegenerative diseases. (2021, Brain research, PMID:33516810)”, “score”: 0.418, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-14-gap-pubmed-20260410-183021-c13d9f04”, “quality_score”: 0.66, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2_20260416-032731”, “title”: “The abstract identifies BACE1 as an attractive drug target but doesn’t address its normal physiological roles. Understanding these functions is critical to predict potential adverse effects of BACE1 inhibitors in therapeutic development.\n\nGap type: open_question\nSource paper: BACE1: the beta-secretase enzyme in Alzheimer’s disease. (2004, Journal of molecular neuroscience : MN, PMID:15126696)”, “score”: 0.401, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-093843-0a9326c2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-08-gap-pubmed-20260406-062132-5d93ddb2_task_9aae8fc5”, “title”: “The review covers various organelle-specific autophagy types but doesn’t address what molecular mechanisms determine which organelles are selectively targeted for autophagy in neurodegeneration. This selectivity mechanism is crucial for understanding disease progression and therapeutic intervention.\n\nGap type: open_question\nSource paper: Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles. (2021, Autophagy, PMID:32048886)”, “score”: 0.364, “reason”: “9 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-08-gap-pubmed-20260406-062132-5d93ddb2”, “quality_score”: 0.655, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}